Jason Ezra Hawkes, MD, MS, FAAD, board-certified dermatologist and associate professor of dermatology at the University of California Davis in Sacramento, spoke on how clinical studies in atopic dermatitis (AD) are increasingly investigating topics that remain unknown for disease management, including primary vs secondary failures and AD pathophysiology across different ethnic groups.
Primary failures vs secondary failures for therapy, differences in pathophysiology across different ethnic groups, and adult-onset disease are 3 key topics that are either being investigated or warrant further study among patients with atopic dermatitis (AD), said Jason Ezra Hawkes, MD, MS, FAAD, board-certified dermatologist and associate professor of dermatology at the University of California Davis in Sacramento.
Transcript
Are there any emerging research you find noteworthy in the management of AD and any gaps in knowledge that warrant further investigation?
In eczema, as well as other dermatologic conditions, we're starting to see better studies where we're looking at 2 things that I think are really important. One is we're starting to pay attention to what we call primary failures and secondary failures. So, with primary failures or nonresponders, these are patients that just never got better, for whatever reason, on a particular therapy, but that's very different from those patients that have done really well for 2 or 3 years and then suddenly stopped responding.
So, I think we've started to appreciate these subtypes within the eczema space, as well as other diseases where we're starting to understand the immune mechanisms that are driving why someone responds to a certain therapy and why people don't or why people lose effectiveness over time and what's driving that. And that's maybe going to ultimately open up this future of predicting response to a particular therapy before starting. So, that would really be a big advance in the treatment of inflammatory conditions.
Another area that I'd like to see more investigation, where we're again starting to have the conversation, is looking at disease in particular subtypes. So, certain ethnic groups' eczema may be a little bit different. So, there's this conversation about eczema in the Western population vs in Asian populations where maybe there's higher levels of IL-17 or other pathways that might be contributing.
I think adult onset vs childhood onset is quite interesting. We learned when I was in medical school and residency that eczema is primarily a disease of childhood. But I'm shocked at how many patients every day that I see who have actually never had disease as children who have true adult-onset disease. We need to understand this phenomenon, why at 50, 60, 70 years of life, they don't have this condition and yet develop it later in life. So, those are areas that I think really warrant further investigation and study so that we can start to tease out these subtypes of a condition we know is heterogeneous in terms of its presentation and also its immunology.
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Decitabine, Venetoclax Combo Boosts Survival in Patients With AML and MDS
May 16th 2024Study findings demonstrate that combining decitabine with venetoclax enhances molecular response rates in patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), correlating strongly with improved clinical outcomes and overall survival.
Read More